- Home
- ROIV vs VNO Comparison
ROIV vs VNO Comparison
Compare ROIV & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- VNO
- Stock Information
- Founded
- ROIV 2014
- VNO 1946
- Country
- ROIV United Kingdom
- VNO United States
- Employees
- ROIV N/A
- VNO N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- VNO Real Estate Investment Trusts
- Sector
- ROIV Health Care
- VNO Real Estate
- Exchange
- ROIV Nasdaq
- VNO Nasdaq
- Market Cap
- ROIV 8.6B
- VNO 7.3B
- IPO Year
- ROIV N/A
- VNO N/A
- Fundamental
- Price
- ROIV $15.09
- VNO $41.92
- Analyst Decision
- ROIV Strong Buy
- VNO Hold
- Analyst Count
- ROIV 9
- VNO 11
- Target Price
- ROIV $19.94
- VNO $38.64
- AVG Volume (30 Days)
- ROIV 8.2M
- VNO 2.0M
- Earning Date
- ROIV 11-11-2025
- VNO 11-03-2025
- Dividend Yield
- ROIV N/A
- VNO 1.75%
- EPS Growth
- ROIV N/A
- VNO 4453.28
- EPS
- ROIV N/A
- VNO 4.07
- Revenue
- ROIV $23,233,000.00
- VNO $1,889,783,000.00
- Revenue This Year
- ROIV N/A
- VNO N/A
- Revenue Next Year
- ROIV $248.22
- VNO $2.94
- P/E Ratio
- ROIV N/A
- VNO $10.37
- Revenue Growth
- ROIV N/A
- VNO 0.58
- 52 Week Low
- ROIV $8.73
- VNO $29.68
- 52 Week High
- ROIV $16.05
- VNO $46.63
- Technical
- Relative Strength Index (RSI)
- ROIV 78.02
- VNO 60.79
- Support Level
- ROIV $13.81
- VNO $41.06
- Resistance Level
- ROIV $16.05
- VNO $42.50
- Average True Range (ATR)
- ROIV 0.50
- VNO 1.12
- MACD
- ROIV 0.22
- VNO 0.24
- Stochastic Oscillator
- ROIV 77.14
- VNO 76.38
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.